On June 24, Wuzhou Medical (301234.SZ) opened the subscription, the subscription price was 26.23 yuan per share, and the subscription limit was 17,000 shares, which belonged to the Growth Enterprise Market.Everbright Securitiesas its sole sponsor.
Founded in 2011, Wuzhou Medical has established a good reputation in the traditional infusion product market by virtue of its highly automated production equipment, mature production technology, perfect product quality control system and quick response service capabilities. At the same time, the company is one of the earliest companies engaged in safety infusion products in China, and some products are currently capable of mass production. In terms of business model, the company has long been focusing on the medical and health care business, implementing the production model of “maintaining production based on sales, independent production, supplemented by outsourced production”, and formulating production plans according to sales orders and customer needs.
Wuzhou Medical said that since its establishment, the company’s main business has been the research and development, production and sales of disposable sterile infusion medical devices, as well as the integrated supply of other diagnostic, nursing and other related medical supplies, mainly through “ODM + integrated supply”. The model meets the one-stop procurement needs of foreign medical device brands for medical supplies. The main products provided by the company to customers include disposable syringes, disposable blood transfusion sets, medical puncture needles, blood pressure monitors, masks, catheters and other medical supplies related to diagnosis and nursing. The product specifications are rich and can be widely used. It is used in clinical injection, infusion and blood transfusion.
The company’s main products are disposable sterile infusion medical device products, which are one of the most widely used basic devices in the medical industry. The iteration of the company’s infusion products is more reflected in improved innovation, which achieves performance iteration or functional optimization for the needs of patients’ condition treatment, clinical or home medical markets, etc. In addition, the company has highly automated production equipment, mature production technology, perfect product quality control system and rapid response service capabilities. The main customers are medical device brands in foreign markets. More than 300 customers in more than 80 countries and regions in North America and Africa have established extensive and continuous cooperative relations.
In terms of product innovation, in recent years, the incidence of needlestick injuries among nurses in various countries has remained high. At present, needle stick injuries have become a major safety concern for nursing staff. In response to the above situation, the company has designed anti-needle stick devices, developed safe injection needles, safe blood collection needles, safe intravenous infusion needles and other safe puncture needle products, and has completed or is in the process of CE certification and FDA product listing, with specifications covering 0.4 mm-1.2mm. Safety products can effectively prevent the occurrence of accidents such as injuries and cross-infection caused by accidental stabbing of medical staff during use, and have good market development prospects;
In addition, in order to meet the diverse needs of customers for medical device products, Wuzhou Medical optimizes and improves the design of the original product, or combines the safety puncture needle with the original product to better improve the performance of the original product and achieve Better clinical treatment effect or improved device safety.
In terms of quality control, Wuzhou Medical passed the ISO13485 quality management system certification in May 2012, and its products passed the EU CE certification, the US FDA510K registration, and the domestic registration and system verification. The company’s product quality management system meets the domestic regulatory requirements. It has twice served as the organizer of the production site training course of the Anhui Provincial Drug Administration, and has passed the US FDA on-site audit twice with the “zero defect” result.
In terms of finance, the operating income of Wuzhou Medical in 2019, 2020 and 2021 will be approximately RMB 487 million, RMB 471 million and RMB 513 million, respectively.
Massive information, accurate interpretation, all in Sina Finance APP